Compare Dishman Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs TORRENT PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA TORRENT PHARMA DISHMAN PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 25.1 38.9 64.6% View Chart
P/BV x 3.3 8.4 39.7% View Chart
Dividend Yield % 0.7 0.7 91.9%  

Financials

 DISHMAN PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
TORRENT PHARMA
Mar-19
DISHMAN PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,964 19.1%   
Low Rs1291,245 10.4%   
Sales per share (Unadj.) Rs197.8453.4 43.6%  
Earnings per share (Unadj.) Rs21.225.8 82.2%  
Cash flow per share (Unadj.) Rs34.762.3 55.7%  
Dividends per share (Unadj.) Rs2.0017.00 11.8%  
Dividend yield (eoy) %0.81.1 75.0%  
Book value per share (Unadj.) Rs179.9279.2 64.4%  
Shares outstanding (eoy) m80.69169.22 47.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.5 36.0%   
Avg P/E ratio x11.962.2 19.1%  
P/CF ratio (eoy) x7.225.8 28.1%  
Price / Book Value ratio x1.45.7 24.3%  
Dividend payout %9.465.9 14.3%   
Avg Mkt Cap Rs m20,306271,513 7.5%   
No. of employees `0000.813.6 6.1%   
Total wages/salary Rs m5,35514,038 38.1%   
Avg. sales/employee Rs Th19,252.75,642.6 341.2%   
Avg. wages/employee Rs Th6,459.51,032.4 625.7%   
Avg. net profit/employee Rs Th2,064.1320.9 643.3%   
INCOME DATA
Net Sales Rs m15,96176,728 20.8%  
Other income Rs m265571 46.5%   
Total revenues Rs m16,22677,299 21.0%   
Gross profit Rs m4,10319,831 20.7%  
Depreciation Rs m1,0916,177 17.7%   
Interest Rs m9445,038 18.7%   
Profit before tax Rs m2,3349,187 25.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m6241,254 49.7%   
Profit after tax Rs m1,7114,363 39.2%  
Gross profit margin %25.725.8 99.5%  
Effective tax rate %26.713.6 195.8%   
Net profit margin %10.75.7 188.5%  
BALANCE SHEET DATA
Current assets Rs m11,01850,375 21.9%   
Current liabilities Rs m9,51751,653 18.4%   
Net working cap to sales %9.4-1.7 -564.7%  
Current ratio x1.21.0 118.7%  
Inventory Days Days11092 120.0%  
Debtors Days Days3568 51.0%  
Net fixed assets Rs m16,30483,648 19.5%   
Share capital Rs m161846 19.1%   
"Free" reserves Rs m12,90746,397 27.8%   
Net worth Rs m14,51647,244 30.7%   
Long term debt Rs m4,18939,129 10.7%   
Total assets Rs m29,805141,209 21.1%  
Interest coverage x3.52.8 122.9%   
Debt to equity ratio x0.30.8 34.8%  
Sales to assets ratio x0.50.5 98.6%   
Return on assets %8.96.7 133.8%  
Return on equity %11.89.2 127.6%  
Return on capital %17.512.3 142.1%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95222,103 22.4%   
Fx outflow Rs m6975,522 12.6%   
Net fx Rs m4,25516,581 25.7%   
CASH FLOW
From Operations Rs m2,78617,981 15.5%  
From Investments Rs m-1,529-2,413 63.4%  
From Financial Activity Rs m-941-13,145 7.2%  
Net Cashflow Rs m3162,380 13.3%  

Share Holding

Indian Promoters % 61.4 71.5 85.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 7.0 52.7%  
FIIs % 12.7 12.6 100.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 8.8 251.1%  
Shareholders   46,261 26,511 174.5%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ORCHID PHARMA LTD  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 143 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day today, tracking weak global cues as coronavirus cases continue to surge across the world.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)

Jun 30, 2020

If you are a trader, you must watch out for this dangerous addiction.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS